Twenty-one patients who underwent cardiac valvular replacement procedures were studied to determine the perioperative changes of plasma endothelin-1 (ET-1) concentration and disposition of ET-1 in the pulmonary and systemic vasculature between patients with elevated (over 20 mmHg) mean pulmonary artery pressure and patients with normal pulmonary artery pressure. The overall profile alterations of plasma ET-1 concentration did not differ between the two groups of patients. The plasma ET-1 levels in the pulmonary artery and right atrium were significantly higher in patients with high pulmonary artery pressure than in patients with normal pulmonary artery pressure. Before cardiopulmonary bypass, significant pulmonary extraction of the plasma ET-1 existed in patients with high pulmonary artery pressure but the pulmonary extraction was not seen after bypass. There was no transpulmonary difference of the plasma ET-1 concentration in patients with normal pulmonary artery pressure either before or after bypass. The high levels of ET-1 in the pulmonary circuit and the pulmonary extraction of the ET-1 in patients with high pulmonary artery pressure might be a protective mechanism for rheumatic valvular patients with elevated pulmonary artery pressure.
Endothelin-1 (ET-1), a potent vasoconstricting peptide released by endothelial cells, has been suggested as important in the development of systemic and pulmonary hypertension 1, 2 . The plasma level of ET-1 has been shown to correlate with the extent of pulmonary hypertension in patients with chronic congestive heart failure 3 , but the exact role ET-1 plays in the pathogenesis of pulmonary hypertension is not known. Yoshibayashi reported that the plasma concentration of ET-1 is increased in the pulmonary artery in children with congenital heart disease and high pulmonary blood flow 4 , whereas other authors have demonstrated that the plasma ET-1 concentrations do not differ between children with or without high pulmonary blood flow in congenital heart disease 5 . Komai and associates have suggested that there is net pulmonary ET-1 extraction, as shown in several previous studies 6, 7 , and possible release of ET-1 from the systemic circulation after cardiac surgery in children with normal or low pulmonary blood flow, but not in children with high pulmonary blood flow 8 . Tonnessen and associates, however, did not demonstrate pulmonary extraction of the plasma ET-1, but showed that there was a marked increase through the left heart chamber 9 . There is only preliminary data about changes of plasma ET-1 levels during cardiac surgery 10 . Furthermore, the disposal of the plasma ET-1 in the systemic and pulmonary circulation in adult patients with valvular heart disease and elevated pulmonary artery pressure (PAP) were not studied.
The purpose of this study was to investigate the perioperative alterations of the plasma ET-1 concentrations across the pulmonary and systemic circulation in patients with or without elevated PAP undergoing cardiac valve replacement.
MATERIALS AND METHODS
Twenty-one patients who underwent surgery for replacement of cardiac valves were studied. Written consent was obtained from every patient, and the study protocol was approved by the Committee of Human Investigation of this institution.
Patients were separated into groups of normal and high PAP in whom the mean PAP, obtained from the preoperative cardiac catheterization record, was higher than 20 mmHg. Anaesthesia was induced with fentanyl 30-50 µg/kg, pancuronium 0.1-0.15 mg/kg, and diazepam 0.3 mg/kg. Electrocardiograph leads II and V5, pulse oximetry, end-tidal carbon dioxide tension, radial artery pressure, nasopharyngeal and rectal temperature and urine output were monitored in every patient. The pulmonary artery catheter was placed in every patient and preoperative haemodynamic data (cardiac output, central venous pressure, mean arterial pressure, pulmonary artery and pulmonary capillary wedge pressure, systemic vascular resistance and pulmonary vascular resistance) were recorded.
In every patient, moderate hypothermic cardiopulmonary bypass (CPB) with lowest nasopharyngeal temperature around 25°C and pulsatile flow with a roller pump (Sarns® 5000, Sarns 3M, Ann Arbor MI, U.S.A.) and membrane oxygenator (Capiox E®, Terumo, Tokyo, Japan) were used. The perfusion flow was kept over 2.2 l/m 2 during normothermia and over 1.8 l/m 2 during hypothermia. The mean arterial pressure was kept between 50 and 100 mmHg during CPB by phenylephrine and phentolamine. The priming solution contained 1.5 to 2 litres of lactated Ringer's solution, mannitol 300 mg/kg, heparin 2000 U/l, and a half to one unit of packed red cells if the predicted haematocrit during bypass was below 22%. Either a CarboMedics® (CarboMedics, Austin TX, U.S.A.) or a St Jude® (St. Jude Medical, St Paul MN, U.S.A.) mechanical prosthesis was used for valve replacements.
Blood samples were taken from the radial artery at the following time points: before induction of anaesthesia, before sternotomy, before commencement of CPB, 10, 30, 60 minutes after the commencement of CPB, at the end of CPB, after infusion of protamine, and 2 and 24 hours after operation. To elucidate the disposition of plasma ET-1 in the left heart chamber, systemic circulation and pulmonary circulation, blood samples were taken from the right atrium, main pulmonary artery, radial artery and left atrium simultaneously before the initiation of CPB and after the infusion of protamine. Four ml of blood was collected into pre-chilled tubes containing 4 mg EDTA and 2000 KIU aprotinin. Samples were centrifuged within half an hour at 4°C and 2000G for 15 minutes. Plasma were stored at -70°C and analysed within a month.
Plasma concentrations of ET-1 were measured with a highly specific radioimmunoassay kit (Peninsula Laboratories, Inc., Belmont, CA). The plasma samples were thawed, acidified with 0.1% trifluoroacetic acid, centrifuged at 2000G at 4°C for 15 minutes and the supernatant extracted with Sep-Column C18 cartridges (Peninsula Laboratories, Inc., Belmont, CA), which was then activated with 60% acetonitrile in 0.1% trifluoroacetic acid. Samples eluted with 2 ml of 60% acetonitrile and 0.1% trifluoroacetic acid were dried using a centrifugal concentrator (SpeedVac; Savant Instruments, Inc., Farmingdale, NY). Radio-immunoassay was performed by a first 24-hour incubation with rabbit anti-ET-1 antibody, addition of 125 I-labeled ET-1 and a second 24-hour incubation. Bound and free 125 I-labeled ET-1 were separated by the second antibody method. The mean recovery of authentic ET-1 after addition to plasma was 71.2 ± 3.5% and the coefficient of variation of the recovery rate was less than 10%. The cross reactions among the ET-1, ET-2, ET-3 and big endothelin were 100%, 7%, 7% and 17%, respectively. The sensitivity of the radioimmunoassay was 1 pg per tube. The intra-assay and inter-assay coefficients of variation were 6.7% and 7.8% in the measurement of the ET-1 concentrations.
Statistical analysis. Student's t-test was used to compare preoperative data between patients with high or normal PAP. The two-way repeated measurement of analysis of variance (ANOVA) was used to compare the profiles of the serial measurements of ET-1 concentrations during cardiac surgery between patients with high PAP and those with normal PAP 11 . Repeated measurements of one-way ANOVA with post hoc Scheffe multiple comparison test were done to compare the values of different time points in each group of patients. Correlation between the perioperative PAP and perioperative ET-1 concentration was analysed using the Pearson's correlation coefficient. Paired t-test was done to compare the differences of ET-1 levels across the pulmonary and systemic circulation. Values were considered to be statistically significant when P was less than 0.05.
RESULTS
The demographic and preoperative haemodynamic data from cardiac catheterization are shown in Table  1 . The operation time, CPB time and ischaemic time did not differ between the high and low PAP groups.
Perioperative haemodynamic measurements are shown in Table 2 . The patients in the high PAP group have higher PAP, CVP, and PCWP preoperatively. The haemodynamic variables were similar postoperatively.
Perioperative changes of plasma ET-1 concentrations in radial artery in both groups are shown in Figure 1 . Preoperative plasma ET-1 concentrations in
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Anaesthesia and Intensive Care, Vol. 24, No. 3, June 1996 the radial artery were higher in patients with high PAP but the difference was not statistically significant (11.89 ± 4.66 vs. 9.82 ± 4.05 pg/ml, P<0.1). In patients with high PAP, plasma ET-1 concentrations decreased after sternotomy and increased toward preoperative levels after the initiation of CPB. In patients with normal PAP, the plasma ET-1 concentrations similarly decreased after sternotomy and remained low during bypass ( Figure 1 ). The results of repeated measurements of two-way ANOVA revealed that the profile of plasma ET-1 concentration changes during operations, which indicates the combined effect of the interaction of the level of PAP and the operative period on the plasma ET-1 concentration did not differ between patients with high PAP and those with normal PAP (Figure 1) .
The alterations of plasma ET-1 concentration across the pulmonary and systemic circulation before and after CPB in these patients are shown in Figure  2 . Before the CPB, the plasma ET-1 concentrations in the pulmonary artery and the right atrium were significantly higher in patients with high PAP than the values obtained from the same sites in patients with normal PAP (13.23 ± 3.80 vs. 8 Values are shown as mean (SD), BSA = body surface area, CPB = cardiopulmonary bypass, PAP = pulmonary artery pressure, PCWP = pulmonary capillary wedge pressure, SVR = systemic vascular resistance, PVR = pulmonary vascular resistance. Values are shown as mean (SD), ABP = mean arterial blood pressure, PAP = pulmonary artery pressure, PCWP = pulmonary capillary wedge pressure, CO = cardiac output, CVP central venous pressure. *P<0.05 compared with normal PAP group. P<0.005, and 11.60 ± 4.00 vs. 7.36 ± 3.30 pg/ml, P<0.05, respectively). Before CPB, plasma ET-1 concentrations in the pulmonary artery were higher than those in the left atrium (13.23 ± 3.80 vs. 8.61 ± 2.97 pg/ml, P<0.01) and plasma ET-1 level in the right atrium was higher than that in the radial artery (11.60 ± 4.00 vs. 8.60± 2.75 pg/ml, P<0.05) in patients with high PAP. On the other hand, preoperative plasma ET-1 concentrations did not differ across the pulmonary and systemic circulation in patients with normal PAP (Figure 2A ). There were no differences in the plasma ET-1 concentrations across the pulmonary and systemic circulation in both groups of patients after CPB. The pulmonary blood flow as measured by the pulmonary artery catheter did not differ between the two groups of patients either before or after CPB. The correlation coefficients between the preoperative arterial plasma ET-1 concentrations and the PAP, pulmonary vascular resistance (PVR) or the pulmonary to systemic vascular resistance ratio were 0.43 (P=0.052), 0.26 (P=0.27) and 0.36 (P=0.10), respectively. There was also no correlation between the perioperative plasma ET-1 concentrations and the perioperative PAP or other haemodynamic variables.
DISCUSSION
The major findings of this study are firstly that the pattern of the alterations of the arterial ET-1 concentration during cardiac operations did not differ between valvular heart disease patients with high and low PAP and secondly, that there was significant transpulmonary difference of the plasma ET-1 concentration in patients with high PAP and this difference disappeared after CPB. Plasma ET-1 concentrations have been reported to be increased in patients with pulmonary hypertension resulting from various aetiologies 4 and to correlate with the extent of pulmonary hypertension in patients with chronic congestive heart failure 12, 13 . Eaton and colleagues, however, could not find any correlation between the plasma ET-1 concentrations sampled from various sites of the circulation and the extent of pulmonary haemodynamic abnormalities in patients with ischaemic and valvular heart disease 14 . On the other hand, Zhu and associates found significant correlation between arterial plasma ET-1 concentration and preoperative PAP and PVR in patients with rheumatic valvular heart disease 15 . In our study we could not find significant correlation between arterial plasma ET-1 concentration with PAP, although we did find that the plasma ET-1 concentrations from pulmonary artery and right atrium were significantly higher in patients with high PAP than in patients with normal PAP. The different patient profiles may in part contribute to the differing results. In the study of Zhu and co-workers, the patients were younger and the severity of pulmonary hypertension was more profound.
Hynynen and associates reported increased immunoreactive ET-1 concentrations during CPB 10 . The rapid decrease of blood pressure immediately
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Anaesthesia and Intensive Care, Vol. 24, No. 3, June 1996 FIGURE 2: Changes to plasma endothelin-1 (ET-1) levels (mean [SEM]) sampled from different sites in valvular heart disease patients with high pulmonary artery pressure (black bar) or normal pulmonary artery pressure (white bar). Plasma ET-1 changes in the pulmonary and systemic circulation before (A) and after cardiopulmonary bypass (B). #: significant differences of ET-1 levels between patients with high and with normal pulmonary artery pressure. LA = left atrium, PA = pulmonary artery, RA = right atrium, Artery = radial artery. after the initiation of CPB 16 may trigger the release of more ET-1 17 in systemic vasculature in patients with high PAP than in patients with normal PAP. The impaired pulmonary ET-1 clearance at low temperatures also contributes to the increase of ET-1 during CPB. The finding that the profile of the alterations of the ET-1 concentrations during CPB did not differ between the two groups of patients suggests that the higher preoperative PAP does not implicate significant change or increase of the ET-1 which might cause pulmonary hypertension after CPB. The different aetiologies of pulmonary hypertension and normalized pulmonary blood flow after surgery in patients with congenital cardiac defects and the different statistical methods 11 used (repeated measurements of two-way ANOVA of the whole series instead of the method of summary measure) may explain different results between this study and the previous one 8 .
Plasma ET-1 has been shown to be extracted in pulmonary circulation in humans 7 . Adatia and associates showed that there were no transpulmonary or arteriovenous differences in plasma ET-1 concentration between congenital heart disease children with either high or low pulmonary blood flow 5 . However, the disposal of plasma ET-1 in the pulmonary circulation in patients with elevated PAP caused by valvular heart disease has not been reported. The increased pulmonary blood flow in patients with congenital heart disease and accompanying pulmonary endothelial damage 18, 19 may decrease the ability of the pulmonary endothelium to remove the plasma ET-1. Since the elevated PAP in patients with valvular heart disease is caused by venous stasis rather than by increased pulmonary blood flow and shear stress 20 , as occurs in congenital heart disease, the nature of pulmonary endothelial damage may be different.
Vincent and associates have suggested that it is the increased pulmonary blood flow rather than pulmonary hypertension that is responsible for the increased ET-1 levels in patients with congenital heart disease 12 . In our study the concentration of ET-1 in the right atrium was higher than that in the radial artery in patients with high PAP. This may reflect secretion of ET-1 by the systemic vascular bed. It is also likely the ET-1 is produced by the endothelium of the right atrium itself and possibly the central veins 21 . The higher PAP may reflect the severity of cardiac dysfunction which is known to be associated with increased secretion of ET-1 21 , reflected by the higher plasma ET-1 levels in the right atrium and pulmonary artery. While it cannot be assumed that the high levels of ET-1 in the pulmonary circuits of patients with elevated PAP are the cause of hyperten-sion (rather than the result of it), it is tempting to ascribe a functional role of ET-1 secretion in the pulmonary arterial circuit to minimize the risk of pulmonary oedema, at least in those patients whose pulmonary hypertension follows back pressure from an obstructed mitral valve or left ventricular failure. In these cases the rise in PAP becomes much higher than can be explained by elevation of pulmonary venous pressure alone, particularly when pulmonary capillary pressure rises considerably above 24 mmHg. It has been postulated that the added resistance is imposed by constriction of the small pulmonary arteries and arterioles and that this may help prevent pulmonary oedema. This would provide a role for ET-1 that is produced in the central veins and right atrium, is active in the pulmonary arteries and is extracted by the lung tissue to prevent undue systemic effects.
There is also another possible role of ET-1 in the pulmonary circulation. Previous reports of possible vasodilatory action of ET-1 on pulmonary vasculature [22] [23] [24] have suggested that it might be one of the protective mechanisms for preventing the development of pulmonary hypertension.
It is possible that the pulmonary endothelium may be injured in cardiac operations during the ischaemia and reperfusion process in CPB 25 . This damage to the pulmonary endothelium during CPB may be mediated through interaction of neutrophils and endothelium, with the involvement of interleukin-8 26, 27 . The endothelial damage may decrease the capability of the plasma endothelium to extract ET-1 8 and may play some role in the development of pulmonary hypertension after CPB 28 . Our findings of similar ET-1 concentration in the radial artery and left atrium do not support the notion that there is significant production of ET-1 through the left heart chamber as reported by other investigators 9 .
We conclude that the perioperative alterations of the plasma ET-1 concentration do not differ between the rheumatic valvular patients with high or normal PAP. There were higher ET-1 levels in the pulmonary circulation and significant pulmonary extraction of plasma ET-1 in patients with high PAP. These findings suggest a possible protective role of ET-1 in rheumatic valvular heart disease patients with elevated PAP.
